Liver CirrhosisNCT01494220
Validation of the Bispectral Index Monitor During Living Donor Liver Transplantation
An observational study of Liver Cirrhosis, run by Mansoura University at 1 site in Egypt.
Trial summary
Bispectral index (BIS) monitoring during living donor liver transplantation (LDLT) may be influenced with several factors rather than the depth of anesthesia such as bradycardia, hypotension, hypothermia, and mixed venous oxygen saturation (SvO2). Read more about this study
- Who is it for?
- Ages 20 to 50 years
- Conditions the study is for
- Liver Cirrhosis
- What is being tested?
- Bispectral index monitoring (BIS)
- Type of treatment
- Medical device
- How many people
- 42 participants
- Where
- 1 siteEgypt
- Study dates
- Jun 2007to Feb 2011
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 20 to 50 years
- All sexes
- No healthy volunteers
- Adult
Study population: Mansoura University Liver Transplantation Program
Who may be able to join
- American Society of Anesthesiologists physical class III-IV
- aged 20-50 years
- severe liver dysfunction
- Child-Pugh Class C
- liver cirrhosis
Who cannot join
- preexisting significant neuropsychiatric
- cardiac diseases
- pulmonary diseases
- renal diseases
- neuromuscular diseases
- electrolyte disorders
Show all 18Show fewer
- body mass index greater than 35 kg/m2
- pregnancy
- use of antipsychotics
- use of antidepressants
- alcohol abuse
- drug abuse
- previous transplantation
- those with hepatic encephalopathy
- recent cognitive dysfunction during the past three months
- fulminant hepatic failure
- hepato-pulmonary syndrome
- pulmonary hypertension
Trial locations and contacts
1 site in 1 country.
About this study
Bispectral index (BIS) monitoring during living donor liver transplantation (LDLT) may be influenced with several factors rather than the depth of anesthesia such as bradycardia, hypotension, hypothermia, and mixed venous oxygen saturation (SvO2). The investigators tested the validity and the independent factors which may alter of BIS readings during LDLT.
Up to the investigators best knowledge, the independent predictors for BIS monitoring were not identified yet during the three phases of liver transplantation.
Read the detailed description
Forty two American Society of Anesthesiologists physical class III-IV patients aged 20-50 years with severe liver dysfunction (Child-Pugh Class C) due to liver cirrhosis undergoing living donor liver transplantation in the Mansoura University Liver Transplantation Program from 2007 to 2010 were included in this prospective, observational study after obtaining approval of the local ethical committee and an informed written consent from all participants. The etiology of liver cirrhosis was hepatitis C, Budd Chiari syndrome, hepatocellular carcinoma and autoimmune in all patients.
Anesthetic technique was standardized for all patients. All patients received preoperative intravenous 40 mg of pantoprazole. Patients were monitored with three leads electrocardiography, pulse oximeter, and noninvasive blood pressure. BIS recording electrodes (Aspect Medical Systems. Inc., One Upland Road, Norwood, MA 02062 USA) were applied to the forehead of each patient according to the manufacturer recommendations. The BIS monitor was masked with opaque sheet and BIS data was recorded prior to induction of general anesthesia then continued throughout the procedure. All information obtained from the BIS monitor was continuously downloaded to a computer for offline analysis. The patient's management was not guided by the changes in BIS readings. Before induction of anesthesia, all patients were premedicated with 1-2 mg of intravenous midazolam.
Independent anesthetists, who were not involved in the collection and analysis of the patient's data, provided the perioperative anesthetic management. After preoxygenation, anesthesia was induced with lidocaine 0.75 mg/kg, propofol 1.5-2.0 mg/kg and fentanyl 2µg/kg. Rocuronium 1-1.2 mg/kg was given to suppress the first response on the train-of-four (TOF) stimulations of the ulnar nerve. After tracheal intubation, the lungs were ventilated with an inspired fraction of oxygen (FiO2) of 0.4 to maintain an arterial carbon dioxide tension at 35-45 mm Hg and monitoring of end-tidal carbon dioxide and sevoflurane concentration, direct arterial pressure monitoring through a radial artery catheter and a tympanic membrane temperature were implemented.
A 7.5 Fr continuous thermodilution fiberoptic pulmonary artery catheter (CCO/SvO2) Edwards Life Science, Irvine, CA, USA) was floated through the right internal jugular vein to the right pulmonary artery using waveform and fluoroscopic guidance to measure cardiac output using Angstrom AS5 Monitor (Datex - Ohmeda AS5, Microvitec Display LTD, Bolling Road, Bradford, UK). The final position was confirmed by fluoroscopy and when PAOP less than pulmonary artery diastolic pressure (PADP).
Anesthesia was maintained with 0.5-1.5 minimum alveolar concentration (MAC) of sevoflurane and continuous intravenous infusion of fentanyl (1-3 µg/kg/h) titrated to maintain the mean arterial blood pressure (MAP) and heart rate (HR) within 20% of their baseline values. Rocuronium 0.1-0.3 mg/kg/h was used to maintain suppression of the second twitch in the TOF.
Normothermia was maintained using intravenous infusions of warm fluid and blood products and water-filled thermal mattress according to the authors' protocol. Fluid boluses were given in 250 ml aliquots of either 5% hydroxyethyl Starch 130/0.4 (Voluven® 6%, Fresenius Kabi, Bad Hombourg, Germany) as needed to maintain the CVP and/or PAOP between 5 and 7 mm Hg and the stroke volume (SV) within 20% of its baseline value. Albumin 5% was given as needed to treat hypoalbuminemia. Transfusion of salvaged blood from the cell saver and packed red blood cells was administered as clinically indicated to maintain a hemoglobin level ≥7 g/dL. Intraoperative changes in electrolyte levels and acid-base balance were regularly monitored and treated as appropriate. Hemodynamic control was standardized according to the authors' center protocol. Hypotension (MAP decreased < 20% from the mean baseline and SVR < 600 dyne.sec-1.cm-5) was treated with boluses of fluids, ephedrine 5 mg, or epinephrine 5 µg, as needed. Norepinephrine infusion was used for persistent hypotension with low SVR. Dobutamine or epinephrine infusion was administered if the MAP was ≥ 70 mm Hg, CVP and/or PAOP ≥ 7 mm Hg and the cardiac output was < 4.0 L. min-1. Hypertension (MAP increased > 20% from the mean baseline) was treated with deepening of anesthesia, bolus doses of nitroglycerin 0.05 mg or labetalol 20 mg. Tachycardia (HR > 20% from the baseline values) was treated with boluses of esmolol 20 mg.
All operations were performed by the same surgeons using the piggyback technique. After portal vein clamping, infusion rates of fentanyl and rocuronium were reduced by approximately 50%. Fentanyl and rocuronium infusions were discontinued after peritoneal closure. After completion of skin closure, sevoflurane was discontinued. The patients were transferred to the ICU immediately after surgery, while intubated and postoperative analgesia was achieved with rescue boluses of fentanyl 0.5 µg/kg when needed.
Extubation criteria included cooperative, alertness, train-of-four ratio ≥ 0.9, spontaneous breathing with tidal volume > 5 mL/kg, respiratory rate > 10 and < 28 breaths/min, maximum inspiratory pressure ≤ -20 cm H2O, stable hemodynamics, minimal bleeding, core temperature > 35.5°C, urine output > 0.5 mL/Kg/h, arterial carbon dioxide tension ≤ 45 mm Hg, arterial oxygen tension > 100 mm Hg and FiO2 < 50%.
On the second postoperative day, the patients were asked about perioperative awareness and recall by asking three simple questions using standard interview "What was the last thing you remembered happening before you went to sleep? What is the first thing you remember happening on waking? Did you dream or have any other experiences whilst you were asleep?" Another investigator, who was not involved in the patient's management, collected the saved patients' data. Preoperative MELD score, durations of warm ischemia and anhepatic phase, intraoperative blood loss and fentanyl consumption were collected. Preoperatively (baseline) absolute values and intraoperative average values for BIS, Et-Sevo, heart rate (HR), MAP, CVP, MPAP, CO, PAOP, SVR, PVR, core temperature, pH, PaCO2, PaO2, SaO2 SvO2, and PvO2 were recorded during hepatic dissection, anhepatic, and neohepatic phases and during surgical closure. Postoperative total bilirubin, albumin level, liver enzymes (AST, ALT, GGT, and alkaline phosphatase), PT, factors V and VII, time to extubation, ICU and hospital length of stays, neurological complication, encephalopathy and 3 months-mortality were recorded.
Data were tested for normality using the Kolmogorov-Smirnov test. Repeated-measures analysis of variance was used for analysis of serial changes in the patients' data at different times. Fisher exact test was used for categorical data. Postulated independent predictors of BIS readings included age, gender, MELD score, durations of surgical phases and warm ischemia, Et-Sevo, average of intraoperative hemodynamic, temperature, oxygenation and acid base variables, intraoperative blood loss and fentanyl consumption, were examined in a stepwise manner into a multiple regression model, with entry and retention set at a significance level of P < 0.05 and removal set at P ≥ 0.1. Moreover, multivariate logistic regression was done to identify the correlations between BIS values and blood loss, time to tracheal extubation, postoperative liver function and coagulation variables, ICU length of stay, and 3 months-mortality.
To evaluate the accuracy of BIS in predicting survival rate after liver transplantation, receiver operating characteristic (ROC) curves were generated to describe the performance characteristics of the BIS readings during different phases of surgery in predicting the survival outcome. An ROC area of 1.0 is characteristic of an ideal model, whereas an area of 0.5 indicates a model of no diagnostic value. Cutoff values for mortality with the best diagnostic sensitivity and specificity were derived from the ROC curve analyses. Unweighted accuracy ((sensitivity + specificity) / 2) was also reported.
The studied patients were further divided according to their outcome variables into survivors (n = 32) and non-survivors (n = 10) subgroups. Independent Student-t- and Mann Whitney tests were used as appropriate. Data were expressed as mean (standard deviation), number (%), or median [range]. A value of P < 0.05 was considered to represent statistical significance.
- Conditions
- Liver Cirrhosis
- Being tested
- Bispectral index monitoring (BIS)
- Keywords
- Bispectral index; anesthesia, liver transplantation, independent factors, outcome, Living donor liver transplantation
- Medical subject headings
- Liver Cirrhosis
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Bispectral index monitoring (BIS)Device
BIS recording electrodes (Aspect Medical Systems. Inc., One Upland Road, Norwood, MA 02062 USA) were applied to the forehead of each patient according to the manufacturer recommendations. The BIS monitor was masked with opaque sheet and BIS data was recorded prior to induction of general anesthesia then continued throughout the procedure. All information obtained from the BIS monitor was continuously downloaded to a computer for offline analysis. The patient's management was not guided by the changes in BIS readings.
| Study group | Role | What they receive |
|---|---|---|
| Living donor liver transplantation | Patients undergoing living donor liver transplantation in the Mansoura University Liver Transplantation Program from 2007 to 2010 Receives: Device: Bispectral index monitoring (BIS) |
What is being measured
The primary outcome is the main question the study is designed to answer.
Intraoperative blood loss
Intraoperative blood loss
Measured: up to 1 hr after surgery
Changes from Baseline in hemodynamic variables
Hemodynamic changes
Measured: 30 min during hepatectomy, 30 min during anhepatic, 30 min during neohepatic phases
Changes from Baseline in Temperature variables
Temperature
Measured: 30 min during hepatectomy, 30 min during anhepatic, 30 min during neohepatic phases
Changes in blood gases variables from baseline
Blood gases
Measured: 30 min during hepatectomy, 30 min during anhepatic, 30 min during neohepatic phases
Secondary outcomes (3)
postoperative liver function tests
correlation between BIS values and postoperative liver function tests
Measured: up to 6 hrs after surgery
postoperative coagulation factors
correlation between BIS and postoperative coagulation factors
Measured: up to 6 hrs after surgery
3-months mortality
correlation between BIS values and 3-months mortality
Measured: up to 3 months after surgery
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted16 Dec 2011 (estimated)
- Study startJun 2007
- Primary completionMar 2010
- Study completionFeb 2011
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Liver CirrhosisStudies of the same condition, open and under way.
- More trials run by Mansoura UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 42 participants (actual)
Sponsor and investigators
- Lead sponsor
- Mansoura University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Mohamed R El Tahan, Mansoura University
- Investigators
- Mohamed R El Tahan, MD, Study director, Anesthesiology Department, Principal Investigator, Clinical Associate Professor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT01494220
- Sponsor's protocol ID
- 2007-5
- Other IDs
- Liver Transplantation Unit 3
- Status last verified
- Apr 2012
- First submitted
- 13 Dec 2011
- Last updated
- 4 Apr 2012
- Results posted
- No
- Data monitoring committee
- Yes
Study at a glance
From the registry record, last updated by the sponsor on 4 Apr 2012. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Validation of the Bispectral Index Monitor During Living Donor Liver Transplantation
- ClinicalTrials.gov ID
- NCT01494220
- Acronym / sponsor ID
- 2007-5
- Conditions
- Liver Cirrhosis
- Keywords
- Bispectral index; anesthesia, liver transplantation, independent factors, outcome, Living donor liver transplantation
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 42 participants (actual)
- Lead sponsor
- Mansoura UniversityUniversity, hospital or other
- Study start
- Jun 2007
- Primary completion
- Mar 2010 (actual)
- Study completion
- Feb 2011 (actual)
- First posted
- 16 Dec 2011 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Bispectral index (BIS) monitoring during living donor liver transplantation (LDLT) may be influenced with several factors rather than the depth of anesthesia such as bradycardia, hypotension, hypothermia, and mixed venous oxygen saturation (SvO2). The investigators tested the validity and the independent factors which may alter of BIS readings during LDLT.
Up to the investigators best knowledge, the independent predictors for BIS monitoring were not identified yet during the three phases of liver transplantation.
Detailed description
Forty two American Society of Anesthesiologists physical class III-IV patients aged 20-50 years with severe liver dysfunction (Child-Pugh Class C) due to liver cirrhosis undergoing living donor liver transplantation in the Mansoura University Liver Transplantation Program from 2007 to 2010 were included in this prospective, observational study after obtaining approval of the local ethical committee and an informed written consent from all participants. The etiology of liver cirrhosis was hepatitis C, Budd Chiari syndrome, hepatocellular carcinoma and autoimmune in all patients.
Anesthetic technique was standardized for all patients. All patients received preoperative intravenous 40 mg of pantoprazole. Patients were monitored with three leads electrocardiography, pulse oximeter, and noninvasive blood pressure. BIS recording electrodes (Aspect Medical Systems. Inc., One Upland Road, Norwood, MA 02062 USA) were applied to the forehead of each patient according to the manufacturer recommendations. The BIS monitor was masked with opaque sheet and BIS data was recorded prior to induction of general anesthesia then continued throughout the procedure. All information obtained from the BIS monitor was continuously downloaded to a computer for offline analysis. The patient's management was not guided by the changes in BIS readings. Before induction of anesthesia, all patients were premedicated with 1-2 mg of intravenous midazolam.
Independent anesthetists, who were not involved in the collection and analysis of the patient's data, provided the perioperative anesthetic management. After preoxygenation, anesthesia was induced with lidocaine 0.75 mg/kg, propofol 1.5-2.0 mg/kg and fentanyl 2µg/kg. Rocuronium 1-1.2 mg/kg was given to suppress the first response on the train-of-four (TOF) stimulations of the ulnar nerve. After tracheal intubation, the lungs were ventilated with an inspired fraction of oxygen (FiO2) of 0.4 to maintain an arterial carbon dioxide tension at 35-45 mm Hg and monitoring of end-tidal carbon dioxide and sevoflurane concentration, direct arterial pressure monitoring through a radial artery catheter and a tympanic membrane temperature were implemented.
A 7.5 Fr continuous thermodilution fiberoptic pulmonary artery catheter (CCO/SvO2) Edwards Life Science, Irvine, CA, USA) was floated through the right internal jugular vein to the right pulmonary artery using waveform and fluoroscopic guidance to measure cardiac output using Angstrom AS5 Monitor (Datex - Ohmeda AS5, Microvitec Display LTD, Bolling Road, Bradford, UK). The final position was confirmed by fluoroscopy and when PAOP less than pulmonary artery diastolic pressure (PADP).
Anesthesia was maintained with 0.5-1.5 minimum alveolar concentration (MAC) of sevoflurane and continuous intravenous infusion of fentanyl (1-3 µg/kg/h) titrated to maintain the mean arterial blood pressure (MAP) and heart rate (HR) within 20% of their baseline values. Rocuronium 0.1-0.3 mg/kg/h was used to maintain suppression of the second twitch in the TOF.
Normothermia was maintained using intravenous infusions of warm fluid and blood products and water-filled thermal mattress according to the authors' protocol. Fluid boluses were given in 250 ml aliquots of either 5% hydroxyethyl Starch 130/0.4 (Voluven® 6%, Fresenius Kabi, Bad Hombourg, Germany) as needed to maintain the CVP and/or PAOP between 5 and 7 mm Hg and the stroke volume (SV) within 20% of its baseline value. Albumin 5% was given as needed to treat hypoalbuminemia. Transfusion of salvaged blood from the cell saver and packed red blood cells was administered as clinically indicated to maintain a hemoglobin level ≥7 g/dL. Intraoperative changes in electrolyte levels and acid-base balance were regularly monitored and treated as appropriate. Hemodynamic control was standardized according to the authors' center protocol. Hypotension (MAP decreased < 20% from the mean baseline and SVR < 600 dyne.sec-1.cm-5) was treated with boluses of fluids, ephedrine 5 mg, or epinephrine 5 µg, as needed. Norepinephrine infusion was used for persistent hypotension with low SVR. Dobutamine or epinephrine infusion was administered if the MAP was ≥ 70 mm Hg, CVP and/or PAOP ≥ 7 mm Hg and the cardiac output was < 4.0 L. min-1. Hypertension (MAP increased > 20% from the mean baseline) was treated with deepening of anesthesia, bolus doses of nitroglycerin 0.05 mg or labetalol 20 mg. Tachycardia (HR > 20% from the baseline values) was treated with boluses of esmolol 20 mg.
All operations were performed by the same surgeons using the piggyback technique. After portal vein clamping, infusion rates of fentanyl and rocuronium were reduced by approximately 50%. Fentanyl and rocuronium infusions were discontinued after peritoneal closure. After completion of skin closure, sevoflurane was discontinued. The patients were transferred to the ICU immediately after surgery, while intubated and postoperative analgesia was achieved with rescue boluses of fentanyl 0.5 µg/kg when needed.
Extubation criteria included cooperative, alertness, train-of-four ratio ≥ 0.9, spontaneous breathing with tidal volume > 5 mL/kg, respiratory rate > 10 and < 28 breaths/min, maximum inspiratory pressure ≤ -20 cm H2O, stable hemodynamics, minimal bleeding, core temperature > 35.5°C, urine output > 0.5 mL/Kg/h, arterial carbon dioxide tension ≤ 45 mm Hg, arterial oxygen tension > 100 mm Hg and FiO2 < 50%.
On the second postoperative day, the patients were asked about perioperative awareness and recall by asking three simple questions using standard interview "What was the last thing you remembered happening before you went to sleep? What is the first thing you remember happening on waking? Did you dream or have any other experiences whilst you were asleep?" Another investigator, who was not involved in the patient's management, collected the saved patients' data. Preoperative MELD score, durations of warm ischemia and anhepatic phase, intraoperative blood loss and fentanyl consumption were collected. Preoperatively (baseline) absolute values and intraoperative average values for BIS, Et-Sevo, heart rate (HR), MAP, CVP, MPAP, CO, PAOP, SVR, PVR, core temperature, pH, PaCO2, PaO2, SaO2 SvO2, and PvO2 were recorded during hepatic dissection, anhepatic, and neohepatic phases and during surgical closure. Postoperative total bilirubin, albumin level, liver enzymes (AST, ALT, GGT, and alkaline phosphatase), PT, factors V and VII, time to extubation, ICU and hospital length of stays, neurological complication, encephalopathy and 3 months-mortality were recorded.
Data were tested for normality using the Kolmogorov-Smirnov test. Repeated-measures analysis of variance was used for analysis of serial changes in the patients' data at different times. Fisher exact test was used for categorical data. Postulated independent predictors of BIS readings included age, gender, MELD score, durations of surgical phases and warm ischemia, Et-Sevo, average of intraoperative hemodynamic, temperature, oxygenation and acid base variables, intraoperative blood loss and fentanyl consumption, were examined in a stepwise manner into a multiple regression model, with entry and retention set at a significance level of P < 0.05 and removal set at P ≥ 0.1. Moreover, multivariate logistic regression was done to identify the correlations between BIS values and blood loss, time to tracheal extubation, postoperative liver function and coagulation variables, ICU length of stay, and 3 months-mortality.
To evaluate the accuracy of BIS in predicting survival rate after liver transplantation, receiver operating characteristic (ROC) curves were generated to describe the performance characteristics of the BIS readings during different phases of surgery in predicting the survival outcome. An ROC area of 1.0 is characteristic of an ideal model, whereas an area of 0.5 indicates a model of no diagnostic value. Cutoff values for mortality with the best diagnostic sensitivity and specificity were derived from the ROC curve analyses. Unweighted accuracy ((sensitivity + specificity) / 2) was also reported.
The studied patients were further divided according to their outcome variables into survivors (n = 32) and non-survivors (n = 10) subgroups. Independent Student-t- and Mann Whitney tests were used as appropriate. Data were expressed as mean (standard deviation), number (%), or median [range]. A value of P < 0.05 was considered to represent statistical significance.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Living donor liver transplantation | – | Device: Bispectral index monitoring (BIS)Patients undergoing living donor liver transplantation in the Mansoura University Liver Transplantation Program from 2007 to 2010 |
Who may qualify
- Ages
- 20 to 50 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult
- Study population
- Mansoura University Liver Transplantation Program
Key inclusion criteria (5 listed)
- American Society of Anesthesiologists physical class III-IV
- aged 20-50 years
- severe liver dysfunction
- Child-Pugh Class C
- liver cirrhosis
Key exclusion criteria (18 listed)
- preexisting significant neuropsychiatric
- cardiac diseases
- pulmonary diseases
- renal diseases
- neuromuscular diseases
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Bispectral index monitoring (BIS)BIS recording electrodes (Aspect Medical Systems. Inc., One Upland Road, Norwood, MA 02062 USA) were applied to the forehead of each patient according to the manufacturer recommendations. The BIS monitor was masked with opaque sheet and BIS data was recorded prior to induction of general anesthesia then continued throughout the procedure. All information obtained from the BIS monitor was continuously downloaded to a computer for offline analysis. The patient's management was not guided by the changes in BIS readings. | Device | Living donor liver transplantation |
Primary outcome
Intraoperative blood loss
Time frame: up to 1 hr after surgery
Intraoperative blood loss
Changes from Baseline in hemodynamic variables
Time frame: 30 min during hepatectomy, 30 min during anhepatic, 30 min during neohepatic phases
Hemodynamic changes
Changes from Baseline in Temperature variables
Time frame: 30 min during hepatectomy, 30 min during anhepatic, 30 min during neohepatic phases
Temperature
Changes in blood gases variables from baseline
Time frame: 30 min during hepatectomy, 30 min during anhepatic, 30 min during neohepatic phases
Blood gases
3 secondary outcomes
postoperative liver function tests
Time frame: up to 6 hrs after surgery
postoperative coagulation factors
Time frame: up to 6 hrs after surgery
3-months mortality
Time frame: up to 3 months after surgery
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 4 Apr 2012.
Related trials for Liver Cirrhosis
RecruitingObservational study
Effectiveness and Clinical Outcomes of Long-term Bulevirtide Monotherapy in Patients With HDV-related Compensated Cirrhosis
Hepatitis D
Recruiting
Optimal Treatment Strategy for Spontaneous Bacterial Peritonitis
Spontaneous Bacterial Peritonitis, Paracentesis
RecruitingObservational study
The Value of Spleen Thickness and Spleen Diameter for Gastroesophageal Varices Diagnosis in Compensated Cirrhosis
Liver Cirrhosis, Gastroesophageal Varices
Recruiting
CirrhosisRx CDS System
Cirrhosis, Decision Support Systems, Clinical
RecruitingPhase 3
Trial to Evaluate ALN-CIDEB in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
Metabolic Dysfunction-Associated Steatotic Liver Disease, MASLD
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Mohamed R El Tahan, MD study director
Anesthesiology Department, Principal Investigator, Clinical Associate Professor
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Liver Cirrhosis, run by Mansoura University at 1 site in Egypt.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 18 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 4 Apr 2012. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Intraoperative blood loss (time frame: up to 1 hr after surgery). The study lists 4 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 4 Apr 2012.